Figures computed from official regulatory filings — .
Analysttarget 1.25 USD (+59%)
Ownershipinsiders 17.4% · institutions 14.8% · short 6.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BeyondSpring Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
63 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Majeti Jiangwen | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Huang Lan | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kirkby Matthew | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Majeti Jiangwen | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lu Yingjuan June | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Xu Sihai | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Huang Lan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fabbio Patrick | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Delaney Brendan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Decheng Capital China Life Sciences USD Fund II, L.P. | Sell | $147.6K | Unusual size | SEC |
| Decheng Capital China Life Sciences USD Fund II, L.P. | Sell | $80.1K | SEC |
| Decheng Capital Global Healthcare GP, LLC | Sell | $29.6K | SEC |
| Decheng Capital Global Healthcare GP, LLC | Sell | $47K | SEC |
| Decheng Capital Global Healthcare GP, LLC | Sell | $182.5K | Unusual size | SEC |
| Decheng Capital Global Healthcare GP, LLC | Sell | $4.2K | SEC |
| Decheng Capital Global Healthcare GP, LLC | Sell | $7.2K | SEC |
| Decheng Capital Global Healthcare GP, LLC | Sell | $13.3K | Unusual size | SEC |
| Decheng Capital Management III (Cayman), LLC | Sell | $1.1K | SEC |
| Decheng Capital Management III (Cayman), LLC | Sell | $31.2K | Unusual size | SEC |
| Decheng Capital Management III (Cayman), LLC | Sell | $3.8K | SEC |
| Cui Xiangmintrack record | Sell | $1K | SEC |
| Cui Xiangmintrack record | Sell | $4.7K | SEC |
| Cui Xiangmintrack record | Sell | $8.1K | SEC |
| Decheng Capital Management III (Cayman), LLC | Sell | $1K | SEC |